Fig. 4From: The time-course of protection of the RTS,S vaccine against malaria infections and clinical diseasePredicted and observed efficacy against clinical disease by 3-monthly periods by trial site for the 5–17 months cohort with booster using best-fitted vaccine profile. Reported efficacy (mean and 95 % CI) in the trial site is indicated by black circles. Prediction estimates in purple (median and 95 % CI)Back to article page